Levi & Korsinsky is investigating the Board of Directors of Immunomedics Inc. (“Immunomedics” or the “Company”) (NASDAQGM:IMMU) for possible violations of federal securities laws. The investigation concerns whether Immunomedics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 28, 2015, UCB SA, Immunomedics’ collaboration partner, announced that their drug epratuzumab failed two Phase 3 studies. Upon the announcement of this news, the share price of Immunomedics stock plunged approximately $1.20, or 32%, in intraday trading from its closing price of $9.71 on July 27, 2015. To obtain additional information, go to:

http://zlk.9nl.com/immunomedicsimmu

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.